IM156 | AMPK activator/Mitochondrial protein complex I inhibitor
NMR (Conforms)
Available Options
| Size: | Price | Quantity | |
|---|---|---|---|
| 5 mg | $60.00 | ||
| 25 mg | $195.00 |
IM156 (1422365-93-2) is a potent activator of AMP-activated protein kinase (AMPK) showing greater activity than metformin or AICAR.1 It displayed protective effects in vivo against peritoneal1, liver2, renal3,and pulmonary fibrosis4. IM156 induces metabolic stress in Myc+ lymphoma cells by inhibiting TCA cycle metabolism and mitochondrial respiration (inhibits mitochondrial protein complex 1).4 IM156 acts as an antiproliferative in several cancer models.5-7
References/Citations:
- Ju et al. (2015), HL156A, a novel AMP-activated protein kinase activator, is protective against peritoneal fibrosis in an in vivo and in vitro model of peritoneal fibrosis; Am. J. Physiol. Renal Physiol.,310 F342
- Lee et al. (2016), AMP-activated protein kinase activator, HL156A reduces thioacetamide-induced liver fibrosis in mice and inhibits the activation of cultured hepatic stellate cells and macrophages; Int. J. Oncol., 49 1407
- Tsogbadrakh et al. (2018), HL156A, a novel pharmacological agent with potent adenosine-monophosphate-activated protein kinase (AMPK) activator ameliorates renal fibrosis in a rat unilateral ureteral obstruction model; PLoS One, 13 e0201692
- Izreig et al. (2020), Repression of LKB1 by mi-17`92 Sensitizes MYC-Dependent Lymphoma to Biguanidine Treatment; Cell Rep. Med., 1 100014
- Choi et al. (2016), Inhibiting stemness and invasive properties of glioblastoma tumorsphere by combined treatment with temozolomide and a newly designed biguanidine (HL156A); Oncotarget, 7 65643
- Jeong et al. (2020), Metformin Derivative HL156A Reverses Multidrug Resistance by Inhibiting HOXC6/ERK1/2 Signaling in Multidrug-Resistant Human Cancer Cells; Pharmaceuticals (Basel), 13 218
- Geiger et al. (2022), First-in-human study of IM156, a novel potent biguanidine oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors; Invest. New Drugs, 40 1001
NMR (Conforms)
Safety Data Sheet:
Product Data Sheet:
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
IM156 (1422365-93-2) is a potent activator of AMP-activated protein kinase (AMPK) showing greater activity than metformin or AICAR.1 It displayed protective effects in vivo against peritoneal1, liver2, renal3,and pulmonary fibrosis4. IM156 induces metabolic stress in Myc+ lymphoma cells by inhibiting TCA cycle metabolism and mitochondrial respiration (inhibits mitochondrial protein complex 1).4 IM156 acts as an antiproliferative in several cancer models.5-7
References/Citations:
- Ju et al. (2015), HL156A, a novel AMP-activated protein kinase activator, is protective against peritoneal fibrosis in an in vivo and in vitro model of peritoneal fibrosis; Am. J. Physiol. Renal Physiol.,310 F342
- Lee et al. (2016), AMP-activated protein kinase activator, HL156A reduces thioacetamide-induced liver fibrosis in mice and inhibits the activation of cultured hepatic stellate cells and macrophages; Int. J. Oncol., 49 1407
- Tsogbadrakh et al. (2018), HL156A, a novel pharmacological agent with potent adenosine-monophosphate-activated protein kinase (AMPK) activator ameliorates renal fibrosis in a rat unilateral ureteral obstruction model; PLoS One, 13 e0201692
- Izreig et al. (2020), Repression of LKB1 by mi-17`92 Sensitizes MYC-Dependent Lymphoma to Biguanidine Treatment; Cell Rep. Med., 1 100014
- Choi et al. (2016), Inhibiting stemness and invasive properties of glioblastoma tumorsphere by combined treatment with temozolomide and a newly designed biguanidine (HL156A); Oncotarget, 7 65643
- Jeong et al. (2020), Metformin Derivative HL156A Reverses Multidrug Resistance by Inhibiting HOXC6/ERK1/2 Signaling in Multidrug-Resistant Human Cancer Cells; Pharmaceuticals (Basel), 13 218
- Geiger et al. (2022), First-in-human study of IM156, a novel potent biguanidine oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors; Invest. New Drugs, 40 1001
Related products
-
ML335 | TREK-1,2 activator
From $55.00CAS:825658-06-8Catalog Number:10-3648Activity:TREK-1,2 activatorChemical Name:N-(2,4-Dichlorobenzyl)-4-(methylsulfonamido)benzamideMolecular Weight:373.25Molecular Formula:C15H14Cl2N2O3SSolubility:Soluble in DMSO (up to 50 mg/ml) or in Ethanol (up to 20 mg/ml with warming).Physical Properties:White solidPurity:98% by TLC
NMR (Conforms)Storage Temperature:-20°Stability:Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 2 months.Shipping Code:RT -
TCEP HCl | Reducing agent
From $35.00CAS:51805-45-9Catalog Number:10-2961Activity:Reducing agentChemical Name:Tris(-Carboxyethyl)phosphine HClMolecular Weight:286.65Molecular Formula:C9H15O6P • HClSolubility:Soluble in Water (up to 50 mg/ml)Physical Properties:White solidPurity:99% by TLC
NMR (Conforms)Storage Temperature:-20°CStability:Stable for 1 year from date of purchase as supplied. Solutions in distilled water may be stored at -20°C for up to 1 month.Shipping Code:RT
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
